Evidence map›Paper›PMID 34302285›Full record

ArticleMolecular biotechnology2021

Identification of a Novel Cleavage Site and Confirmation of the Effectiveness of NgAgo Gene Editing on RNA Targets.

Jiayao Qu, Yali Xie, Zhaoyi Guo, Xiangting Liu, Jing Jiang, Ting Chen, Kai Li, Zheng Hu, Dixian Luo

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular biotechnology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
3.3field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Jiayao Qu *Laboratory Medicine Center, Huazhong University of Science and Technology Union Shenzhen Hospital (Nanshan Hospital), Shenzhen, 518000, Guangdong, People's Republic of China.
Yali Xie *Translational Medicine Institute, National & Local Joint Engineering Laboratory for High-Through Molecular Diagnosis Technology, The First People's Hospital of Chenzhou, University of South China, 102 Luojiajing Road, Chenzhou, 432000, Hunan, People's Republic of China.
Zhaoyi GuoLaboratory Medicine Center, Huazhong University of Science and Technology Union Shenzhen Hospital (Nanshan Hospital), Shenzhen, 518000, Guangdong, People's Republic of China.
Xiangting LiuTranslational Medicine Institute, National & Local Joint Engineering Laboratory for High-Through Molecular Diagnosis Technology, The First People's Hospital of Chenzhou, University of South China, 102 Luojiajing Road, Chenzhou, 432000, Hunan, People's Republic of China.
Jing JiangTranslational Medicine Institute, National & Local Joint Engineering Laboratory for High-Through Molecular Diagnosis Technology, The First People's Hospital of Chenzhou, University of South China, 102 Luojiajing Road, Chenzhou, 432000, Hunan, People's Republic of China.
Ting ChenTranslational Medicine Institute, National & Local Joint Engineering Laboratory for High-Through Molecular Diagnosis Technology, The First People's Hospital of Chenzhou, University of South China, 102 Luojiajing Road, Chenzhou, 432000, Hunan, People's Republic of China.
Kai LiTranslational Medicine Institute, National & Local Joint Engineering Laboratory for High-Through Molecular Diagnosis Technology, The First People's Hospital of Chenzhou, University of South China, 102 Luojiajing Road, Chenzhou, 432000, Hunan, People's Republic of China.
Zheng HuTranslational Medicine Institute, National & Local Joint Engineering Laboratory for High-Through Molecular Diagnosis Technology, The First People's Hospital of Chenzhou, University of South China, 102 Luojiajing Road, Chenzhou, 432000, Hunan, People's Republic of China. hu48005@163.com.ORCID http://orcid.org/0000-0002-4078-5450
Dixian LuoLaboratory Medicine Center, Huazhong University of Science and Technology Union Shenzhen Hospital (Nanshan Hospital), Shenzhen, 518000, Guangdong, People's Republic of China. luodixian_2@163.com.ORCID http://orcid.org/0000-0001-6155-8137
Chenzhou First People's Hospital · CNShenZhen People’s Hospital · CN

Funding

Hunan Province Science Fund for Distinguished Young Scholars 2018JJ1021the Health Department project of the Hunan Province B2017182, B20180378, B20180266the Hunan Province Technological Innovation Guiding Plan, Clinical Medical Technology Innovation Guidance Project 2017SK51101the Key R&D Program of Hunan Province 2017SK2172the Natural Science Foundation of Hunan Province 2017JJ2003the Natural Science Foundation of Hunan Province 2017JJ2004the Science and Technique Foundation of Chenzhou jsyf2017021, jsyf2017023 and zdyf201838)
6 · The paper itself

Abstract

Clusters of regularly interspaced short palindromic repeats (CRISPR)/Cas systems have a powerful ability to edit DNA and RNA targets. However, the need for a specific recognition site, protospacer adjacent motif (PAM), of the CRISPR/Cas system limits its application in gene editing. Some Argonaute (Ago) proteins have endonuclease functions under the guidance of 5' phosphorylated or hydroxylated guide DNA (gDNA). The NgAgo protein might perform RNA gene editing at 37 °C, suggesting its application in mammalian cells; however, its mechanisms are unclear. In the present study, the target of NgAgo in RNA was confirmed in vitro and in vivo. Then, an in vitro RNA cleavage system was designed and the cleavage site was verified by sequencing. Furthermore, NgAgo and gDNA were transfected into cells to cleave an intracellular target sequence. We demonstrated targeted degradation of GFP, HCV, and AKR1B10 RNAs in a gDNA-dependent manner by NgAgo both in vitro and in vivo, but no effect on DNA was observed. Sequencing demonstrated that the cleavage sites are located at the 3' of the target RNA which is recognized by 5' sequence of the gDNA. These results confirmed that NgAgo-gDNA cleaves RNA not DNA. We observed that the cleavage site is located at the 3' of the target RNA, which is a new finding that has not been reported in the past.

Indexed as

Archaeal ProteinsArgonaute ProteinsCell LineCRISPR-Cas SystemsGene EditingHEK293 CellsHumansNatronobacteriumRNA, Guide, CRISPR-Cas SystemsRNA SplicingArchaeal ProteinsArgonaute ProteinsRNA, Guide, CRISPR-Cas SystemsAgoArgonauteCleavage sitegDNANgAgoRNA editing

Identifiers

PMID34302285
OpenAlexW3186155478

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.